Skip to main content
NVDA+0.96%AAPL+0.04%GOOGL+0.86%MSFT+0.87%AMZN+0.71%TSM+2.75%SPCX+7.63%META+0.36%AVGO+2.08%TSLA+1.16%SKHY-0.06%MU+0.06%BRK-B+0.32%LLY+0.02%AMD-0.34%JPM0.00%WMT+0.78%ASMLa+0.74%V+2.51%XOM+0.01%JNJ-1.21%INTC-2.63%0700.HK+1.23%MA+2.23%ABBV+1.12%1398.HK+1.61%CSCO+0.55%LRCX-0.49%AP2d+1.22%AMAT+0.41%CVX-0.11%ORCL+0.18%COST+0.31%CAT+0.32%BAC+0.47%KO+1.00%DELL-1.86%PG+0.71%UNH+1.80%0005.HK+1.93%HSBA.L+0.88%3988.HK+1.69%ARM-1.49%1816.HK+0.48%GE-1.04%0857.HK+1.04%MS-0.06%0939.HK+1.47%PM+1.10%1288.HK+0.92%PLNJPY+0.76%USDPLN-0.72%USDZAR-0.71%AUDCHF+0.63%USDMXN-0.58%USDSEK-0.53%AUDJPY+0.50%CHFSEK-0.47%GBPCHF+0.43%GBPTRY+0.41%EURHKD+0.41%USDDKK-0.39%AUDUSD+0.36%EURCNH+0.34%AUDCAD+0.34%AUDNZD+0.34%GBPZAR-0.33%EURPLN-0.33%GBPHKD+0.32%GBPJPY+0.31%EURZAR-0.31%NZDMXN-0.29%GBPMXN-0.28%EURCHF+0.28%NOKJPY+0.28%AUDDKK-0.26%EURAUD-0.25%GBPUSD+0.25%EURSGD+0.24%USDNOK-0.24%GBPCAD+0.24%GBPNZD+0.23%GBPSGD+0.22%NZDCHF+0.21%USDCHF+0.19%CADCHF+0.19%SGDJPY+0.18%CHFNOK-0.18%EURJPY+0.17%EURCZK-0.17%USDILS+0.16%EURNOK+0.16%GBPAUD-0.15%USDSGD-0.15%NZDSGD+0.14%EURSEK-0.14%EURGBP-0.13%AUDNOK-0.12%CHFJPY-0.11%EURUSD+0.11%NZDJPY+0.11%USDTRY+0.11%USDTHB+0.10%EURCAD+0.10%EURNZD+0.10%USDJPY+0.10%CHFSGD-0.09%CADJPY+0.09%USDCNH-0.05%USDCOP-0.04%AUDSGD-0.02%NZDCAD+0.01%NZDUSD+0.01%EURDKK+0.01%USDHKD+0.01%USDCAD0.00%UKOIL-2.43%USOIL-2.09%COCOA-1.36%W1+1.14%C1+0.83%COFFEE+0.82%GAUUSD+0.69%XAUUSD+0.69%COTTON+0.60%GAGUSD+0.57%XAGUSD+0.55%S1+0.52%BTCUSD+0.65%ETHUSD+6.15%USDTUSD-0.04%XRPUSD-0.54%SOLUSD-2.00%TRXUSDT-0.15%ZECUSDT+2.33%DOGEUSD-1.82%XMRUSDT-0.76%LINKUSD+3.21%XLMUSD+0.53%BCHUSDT+0.38%UNIUSD-2.22%LTCUSD-4.60%SUIUSD-0.96%HBARUSDT-0.25%TONUSD+12.52%TAOUSDT-0.59%AAVEUSD-1.26%DOTUSDT+0.28%ICPUSDT-4.15%ONDOUSDT+0.14%WLDUSDT+0.47%ARBUSDT-3.10%JUPUSDT-0.14%ATOMUSDT-0.58%INJUSDT+0.80%STXUSDT+0.08%FETUSDT-1.98%SEIUSDT-0.61%PYTHUSDT+1.02%TIAUSDT-1.42%IMXUSDT-1.75%GRTUSDT-0.64%OPUSDT-2.99%WIFUSDT+0.80%IOTAUSDT+4.29%AXSUSDT-0.24%POLUSDT+1.35%FARTCOINUSDT+2.13%EOSUSDT+3.34%DYDXUSDT-1.68%GALAUSDT-0.12%ORDIUSDT+1.11%NOTUSDT+1.29%RONINUSDT+2.94%NVDA+0.96%AAPL+0.04%GOOGL+0.86%MSFT+0.87%AMZN+0.71%TSM+2.75%SPCX+7.63%META+0.36%AVGO+2.08%TSLA+1.16%SKHY-0.06%MU+0.06%BRK-B+0.32%LLY+0.02%AMD-0.34%JPM0.00%WMT+0.78%ASMLa+0.74%V+2.51%XOM+0.01%JNJ-1.21%INTC-2.63%0700.HK+1.23%MA+2.23%ABBV+1.12%1398.HK+1.61%CSCO+0.55%LRCX-0.49%AP2d+1.22%AMAT+0.41%CVX-0.11%ORCL+0.18%COST+0.31%CAT+0.32%BAC+0.47%KO+1.00%DELL-1.86%PG+0.71%UNH+1.80%0005.HK+1.93%HSBA.L+0.88%3988.HK+1.69%ARM-1.49%1816.HK+0.48%GE-1.04%0857.HK+1.04%MS-0.06%0939.HK+1.47%PM+1.10%1288.HK+0.92%PLNJPY+0.76%USDPLN-0.72%USDZAR-0.71%AUDCHF+0.63%USDMXN-0.58%USDSEK-0.53%AUDJPY+0.50%CHFSEK-0.47%GBPCHF+0.43%GBPTRY+0.41%EURHKD+0.41%USDDKK-0.39%AUDUSD+0.36%EURCNH+0.34%AUDCAD+0.34%AUDNZD+0.34%GBPZAR-0.33%EURPLN-0.33%GBPHKD+0.32%GBPJPY+0.31%EURZAR-0.31%NZDMXN-0.29%GBPMXN-0.28%EURCHF+0.28%NOKJPY+0.28%AUDDKK-0.26%EURAUD-0.25%GBPUSD+0.25%EURSGD+0.24%USDNOK-0.24%GBPCAD+0.24%GBPNZD+0.23%GBPSGD+0.22%NZDCHF+0.21%USDCHF+0.19%CADCHF+0.19%SGDJPY+0.18%CHFNOK-0.18%EURJPY+0.17%EURCZK-0.17%USDILS+0.16%EURNOK+0.16%GBPAUD-0.15%USDSGD-0.15%NZDSGD+0.14%EURSEK-0.14%EURGBP-0.13%AUDNOK-0.12%CHFJPY-0.11%EURUSD+0.11%NZDJPY+0.11%USDTRY+0.11%USDTHB+0.10%EURCAD+0.10%EURNZD+0.10%USDJPY+0.10%CHFSGD-0.09%CADJPY+0.09%USDCNH-0.05%USDCOP-0.04%AUDSGD-0.02%NZDCAD+0.01%NZDUSD+0.01%EURDKK+0.01%USDHKD+0.01%USDCAD0.00%UKOIL-2.43%USOIL-2.09%COCOA-1.36%W1+1.14%C1+0.83%COFFEE+0.82%GAUUSD+0.69%XAUUSD+0.69%COTTON+0.60%GAGUSD+0.57%XAGUSD+0.55%S1+0.52%BTCUSD+0.65%ETHUSD+6.15%USDTUSD-0.04%XRPUSD-0.54%SOLUSD-2.00%TRXUSDT-0.15%ZECUSDT+2.33%DOGEUSD-1.82%XMRUSDT-0.76%LINKUSD+3.21%XLMUSD+0.53%BCHUSDT+0.38%UNIUSD-2.22%LTCUSD-4.60%SUIUSD-0.96%HBARUSDT-0.25%TONUSD+12.52%TAOUSDT-0.59%AAVEUSD-1.26%DOTUSDT+0.28%ICPUSDT-4.15%ONDOUSDT+0.14%WLDUSDT+0.47%ARBUSDT-3.10%JUPUSDT-0.14%ATOMUSDT-0.58%INJUSDT+0.80%STXUSDT+0.08%FETUSDT-1.98%SEIUSDT-0.61%PYTHUSDT+1.02%TIAUSDT-1.42%IMXUSDT-1.75%GRTUSDT-0.64%OPUSDT-2.99%WIFUSDT+0.80%IOTAUSDT+4.29%AXSUSDT-0.24%POLUSDT+1.35%FARTCOINUSDT+2.13%EOSUSDT+3.34%DYDXUSDT-1.68%GALAUSDT-0.12%ORDIUSDT+1.11%NOTUSDT+1.29%RONINUSDT+2.94%
CR

Charles River Laboratories International, Inc. (CRL)

NYSE • Healthcare

$310.77
+$20.57 (+7.1%)
Market closed

Last close at October 5, 2026 at 20:00 UTC

Open$292.05
Day Range$292.02 - $312.26
Avg. Volume (3M)988.7K
Market Cap$14.9B
52 Week Range
$146.2$312.26
Next EarningsIn 29 daysNov 4, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$1B100%
Gross Profitminus cost of goods$363.3M36%
Operating Incomeminus R&D and overhead$119.8M12%

Fundamentals & Financials

Revenue (TTM)
$3.9B
Net Income (TTM)
-$238.4M
EPS (TTM)
-$4.84
ROA (TTM)
-3.17%
Current Ratio
1.35
Dividend Yield
0%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+2.6%Q1 2026$2.39
+5.1%Q2 2026$2.06
+10.2%Q3 2026$3.02
Next

Nov 4

in 29 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Beat +10.2%

Charles River Laboratories International beat expectations on both the top and bottom line in the second fiscal quarter of 2026, based on preliminary results reported Aug. 5. Revenue fell 3% to about $1.0 billion from $1.03 billion a year ago, but still came in above the $977.2 million estimate by 2.8%, while adjusted EPS of $3.02 topped the $2.77 consensus by 9% and was down 3% from $3.12 a year earlier. Operating income of about $119.9 million left operating margin near 12%, and operating cash flow was $179.7 million as the company repurchased about $115.6 million of stock. Consensus for the next period calls for EPS of $3.05 on revenue of $941.8 million.

Next report — what to expect

Charles River Laboratories International, Inc. (CRL) reports on November 4, 2026. Wall Street looks for EPS of $2.97 on revenue of $959.0 million. For trailing context, revenue declined -2.7% year over year last quarter. CRL has beaten EPS in 8 of 8 most recent quarters; focus on revenue and margin commentary versus expectations.

View full earnings history

About Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. is a healthcare research-services company listed on the NYSE under CRL that supports pharmaceutical and biotechnology customers across preclinical drug development, laboratory testing, and research model supply. Its operations produced $4.0 billion of revenue in FY2025.

Name
Charles River Laboratories International, Inc.
CEO
Birgit Girshick
Website
www.criver.com
Industry
Healthcare
Year Founded
1947
Employees
19,000

Today's Snapshot

AI-generated

The day ended with CRL 7.1% higher at 310.88, in line with a firmer sector. At the close, CRL was within 0.2% of its 52-week high of 311.54.

Trading Volume

Above 10d avg 991.5K

1.1M

vs S&P 500 Today

Strong Outperformance

+6.37%

Updated: October 5, 2026 at 20:05 UTC

CRL Headlines

Citi Resets Life Sciences And MedTech Views

March 11, 2026

5 min read
View All News

Technical Indicators

6 Buy2 Neutral0 Sell
CRL exhibits a robust bullish setup with the price around 310.77 and clear strength across moving averages as short- and medium-term averages sit well above the 200-day, signaling broad upside participation. Momentum readings are strong, including a positive MACD and elevated CCI, while trend strength is constructive (ADX about 27.3) and on-balance volume is positive, supporting the advance. Volatility is moderate with an ATR near $10, and the classic pivot lies below the current price, acting as support rather than resistance. Technical takeaway: Strong Buy — sustained momentum and broad moving-average support underpin a bullish stance.
All signals
  • EMA (5 indicators)$222.71 - $292.96
    Buy
  • RSI (14)67.04
    Neutral
  • Stochastic %K (14, 3, 3)75.94
    Neutral
  • MACD Level (12, 26)5.90
    Buy

Peers & Related Assets

RVTYRevvity, Inc.
$157.36+3.9%
BAXBaxter International Inc.
$24.22+3.1%
PENPenumbra, Inc.
$317.11-0.1%
DVADaVita Inc.
$178.72+0.0%
AVTRAvantor, Inc.
$15.81+3.1%
BIOBio-Rad Laboratories, Inc.
$379.82+2.9%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.